Symposium
Session Room: Carron
Session Room: Carron
Sunday, June 28, 02:40 PM – 03:55 PM
Symposium 17:
LSD in Anxiety: How does it work?
LSD in Anxiety: How does it work?
Recent clinical data have shown potential efficacy of lysergic acid diethylamide (LSD) for treating anxiety and comorbid addictive disorders. A single or double administration produces sustained effects lasting several weeks, unlike standard treatments that require daily use over months or fast-acting agents with only transient relief. This symposium will present new, unpublished data on the anxiolytic effects of LSD across preclinical and clinical domains. The goal is to deeply understand LSD’s mechanism of action through translational perspectives, bridging molecular, systems-level, and clinical insights.
Dr. Gabriella Gobbi (Full Professor, Department of Psychiatry, McGill University, Montreal, Canada) will present preclinical data showing how LSD affects behavior in anxiety-related paradigms and modulates in vivo neuronal firing patterns and EEG markers of arousal and emotional reactivity.
Dr Danilo De Gregorio (San Raffaele Hospital and University, Milan, Italy) will present data concerning the ability of a single administration of LSD in reducing alcohol consumption and comorbid anxiety in a preclinical model of alcohol use disorder .
Dr. Friederike Holze (University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland) will present secondary analyses from a recent double-blind, placebo-controlled trial in patients with anxiety disorders, either associated with a life-threatening illness or not. Participants received two administrations of 200 µg LSD separated by six weeks. Patients were enrolled in the trial for 48 weeks and underwent a follow-up assessment one year later. Dr. Holze will discuss predictors of the short and long-term therapeutic response, including sex differences, personality traits, acute effects, and baseline characteristics.
Dr. Gabriella Gobbi (Full Professor, Department of Psychiatry, McGill University, Montreal, Canada) will present preclinical data showing how LSD affects behavior in anxiety-related paradigms and modulates in vivo neuronal firing patterns and EEG markers of arousal and emotional reactivity.
Dr Danilo De Gregorio (San Raffaele Hospital and University, Milan, Italy) will present data concerning the ability of a single administration of LSD in reducing alcohol consumption and comorbid anxiety in a preclinical model of alcohol use disorder .
Dr. Friederike Holze (University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland) will present secondary analyses from a recent double-blind, placebo-controlled trial in patients with anxiety disorders, either associated with a life-threatening illness or not. Participants received two administrations of 200 µg LSD separated by six weeks. Patients were enrolled in the trial for 48 weeks and underwent a follow-up assessment one year later. Dr. Holze will discuss predictors of the short and long-term therapeutic response, including sex differences, personality traits, acute effects, and baseline characteristics.
03:30 PM – 03:55 PM
25 min
25 min